Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

The CFO's share sale was made under a pre-set plan and is not a bearish signal

The CFO's share sale was made under a pre-set plan and is not a bearish signal. The sell side has no consensus on how to value peptides, so the real re-rating window is the 11 May earnings report and the 23 Jul FDA advisory committee. After a 48% gain in a week, the narrative has moved from GLP-1 risk to peptide opportunity, and chasing the move in the short term calls for caution.

Analyst views

BofA

Raised its target from $21 to $25 (peptides a positive), then cut it back to $21 (worried that a GLP-1 revenue decline of about 50% will weigh on EBITDA)

Consensus

The average target price of 17 analysts is $31.71 and the shares have already touched $31, so the consensus target is largely priced in

Key uncertainty

The sell side has no consensus at all on how to value peptides

Leerink

Maintained its $25 target: peptides will not turn into revenue in the short term, but their strategic value is clear

CFO insider sale

Conclusion

A routine plan sale, not a bearish signal

Plan

All sales were made under a Rule 10b5-1 plan adopted on 21 May 2025, so they were not reactive

Remaining holdings

288,051 shares held directly, 7,853 shares in trust and 129,403 unexercised options

Summary

CFO Oluyemi Okupe sold 54,927 shares (about $1.46 million) on 16-17 Apr and exercised options over 6,184 shares (exercise price $5.01)

Price action

Media

Heavy coverage in mainstream media such as Forbes

Move

Up 48% in a week, surging from the $21 range to $31

Narrative shift

From 'GLP-1 risk stock' to 'peptide opportunity and platform re-rating'

Risk flag

The short-term gain is huge and the stock is in overbought territory, so a pullback is a real possibility. Medium-term catalysts are clear, but chasing the move in the short term calls for caution.

Catalysts to watch

  • 11 May Q1 earnings: management sets out its peptide strategy
  • Outcome of the FDA advisory committee on 23-24 Jul

A brief is a lead for our research, not a verified conclusion or advice.